Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Bardet-Biedl Syndrome - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
Key Highlights
- Bardet-Biedl syndrome (BBS) is a rare autosomal recessive condition with at least twenty gene implications. It includes alternative names like Laurence-Moon-Biedl-Bardet syndrome, among others.
- There is clinical overlapping between Bardet-Biedl syndrome (BBS) and Senior-Loken and Alstrom syndromes in adults.
- In 2022, the FDA approved IMCIVREE (setmelanotide) for the treatment of obesity in Bardet-Biedl Syndrome (BBS) and Alstrom syndrome patients 6 years and older.
- IMCIVREE is the first approved treatment for BBS, emphasizing the absence of emerging drugs.
- The United States leads the market size for Bardet-Biedl syndrome (BBS) over EU4, the United Kingdom, and Japan.
The "Bardet-Biedl syndrome (BBS) - Market Insights, Epidemiology and Market Forecast - 2036" report offers a comprehensive understanding of BBS's epidemiology, historical and forecasted data, and market trends across key regions including the US, EU4, the UK, and Japan.
The report details the real-world prescription patterns, market share of therapies, and historical and forecasted market sizes from 2022 to 2036. Insights into treatment algorithms and unmet medical needs are explored to highlight market potential.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Bardet-Biedl syndrome (BBS) Understanding and Treatment Algorithm
Bardet-Biedl syndrome (BBS) affects multiple body systems, manifesting in symptoms like vision deterioration, obesity, extra digits, cognitive impairments, and reproductive abnormalities. Kidney issues, speech delays, and motor coordination problems are also prevalent. Diagnosis integrates clinical features and genetic testing, identifying known mutations in approximately 80% of cases.
Bardet-Biedl syndrome (BBS) Treatment
Comprehensive care involving various specialists is crucial for BBS management. Early treatment facilitates improved outcomes. Surgical and hormonal interventions may address specific physical problems. Managing obesity involves diet, exercise, and possibly bariatric surgery. Regular eye care is essential to tackle vision challenges while educational support services are important due to learning impacts.
Bardet-Biedl syndrome (BBS) Epidemiology
Our report offers an analysis of BBS epidemiology from 2026 to 2036 in key regions, segmenting data according to clinical manifestations and genetic mutations. BBS1 and BBS10 are primary genes implicated, present in over 20% of cases, with equal male and female prevalence. Retinal dystrophy is a key feature, affecting nearly all patients, followed by high rates of obesity.
Marketed Drugs
IMCIVREE: Rhythm Pharmaceuticals is used for long-term weight management in children and adults with Bardet-Biedl Syndrome. It acts on MC4 receptors to regulate hunger and energy, aiding in reduced caloric intake and enhanced energy expenditure.
Emerging Drugs
AXV-101: Axovia Therapeutics is a gene therapy in early clinical phases for BBS treatment, focusing on vision impairment and systemic symptoms. It holds Orphan Drug and Rare Pediatric Disease designations by the FDA.
Bardet-Biedl syndrome (BBS) Market Outlook
Currently, only IMCIVREE is approved for BBS, with no emerging drugs being actively trialed. Addressing symptoms remains the treatment focus, with unmet needs pointing to critical areas for research and support expansion.
KOL Views
Feedback from industry leaders validates treatment patterns and highlights gaps in research, contributing to shaping future market strategies for novel BBS interventions.
Qualitative Analysis
Through SWOT and Conjoint Analysis, we assess gaps in disease management, therapy effectiveness, market threats, and opportunities, alongside safety and success probabilities of emerging treatments.
Market Access and Reimbursement
Insights on the accessibility and affordability of therapies, including federal or state program coverage, add layers to the financial landscape of BBS treatment.
Scope of the Report
- Detailed analysis of BBS, covering its etiology, symptoms, and available treatments.
- Assessment of epidemiological trends and treatment guidelines specific to each region.
- Coverage of current and future therapies, highlighting significant market and therapeutic dynamics.
- Strategic insights guiding business planning based on market trends, SWOT analysis, and expert opinions.
Bardet-Biedl syndrome (BBS) Report Insights
- Patient Population
- Therapeutic Approaches
- Bardet-Biedl syndrome (BBS) Pipeline Analysis
- Bardet-Biedl syndrome (BBS) Market Size and Trends
- Existing and future Market Opportunity
Bardet-Biedl syndrome (BBS) Report Key Strengths
- Eleven Years Forecast
- 7MM Coverage
- Bardet-Biedl syndrome (BBS) Epidemiology Segmentation
- Inclusion of Country-specific treatment guidelines
- KOL's feedback on approved and emerging therapies
- Key Cross Competition
- Drugs Uptake and Key Market Forecast Assumptions
Bardet-Biedl syndrome (BBS) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Market Attractiveness
- Qualitative Analysis (SWOT)
FAQs
- What is the growth rate of the 7MM Bardet-Biedl syndrome (BBS) treatment market?
- Contributing factors to the BBS market size changes from 2022 to 2036?
- Is there potential for unexplored patient settings?
- Pricing and accessibility challenges across regions?
- How do market dynamics influence trends and analysis?
- Current and emerging treatment options for BBS?
- Companies involved in therapy development for BBS?
- Recent innovations targeting therapy limitations?
- Patient/physician acceptability in treatment patterns?
- Accessibility barriers for recent therapies?
Reasons to buy
- Helps in strategy development by understanding market trends and dynamics.
- Insights into patient burden and disease epidemiology shifts.
- Identifying growth opportunities in various geographies.
- Shares historical and current patient data with sales across key markets.
- Spotlights strong market players for strategic planning.
- Highlights of access and reimbursement strategies.
- Strategies to overcome accessibility and compliance challenges.
- Understanding unmet market needs for development and launch strategy.
For more information about this report visit https://www.researchandmarkets.com/r/h5rtdj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
